Skip to main content

Table 3 Secondary endpoints power analysis

From: Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial

Secondary Endpoint Assumed Rate in CT-Guided SBRT Arm Absolute Difference at 80% Power (n = 150 per arm)
Acute grade ≥ 2 GI toxicity 16.0% 8.3%
Late grade ≥ 2 GU toxicity 13.3% 12.8%
Late grade ≥ 2 GI toxicity 2.0% 7.5%